<DOC>
	<DOCNO>NCT02655679</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics , pharmacodynamics preliminary clinical efficacy VTP-38543 administer cream , twice-daily , 28 day otherwise healthy adult male female patient mild moderate atopic dermatitis .</brief_summary>
	<brief_title>An Ascending Multiple Dose Study VTP-38543 Adult Patients With Mild Moderate Atopic Dermatitis</brief_title>
	<detailed_description>This randomize , double-blind , vehicle-controlled study evaluate safety , tolerability , pharmacokinetics , pharmacodynamics preliminary clinical efficacy VTP-38543 follow twice-daily , every twelve hour ( Q12h ) administration 28 day otherwise healthy adult male female patient mild moderate atopic dermatitis . Evaluation three ascend dos three patient panel plan trial . Dose Panel 1 2 enroll 30 patient randomize 20 VTP-38543 10 matching vehicle control ( Vehicle 1 ) . Dose Panel 3 enroll 40 patient randomize 20 VTP-38543 20 matching vehicle control ( Vehicle 2 ) . A total approximately 100 patient participate trial .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Mild moderate atopic dermatitis minimum 3 maximum 15 % body surface area ( BSA ) involvement IGA score 2 3 BMI = 18 35 kg/m2 Medically healthy ( exclusive atopic dermatitis ) Negative Pregnancy test female Treatment atopic dermatitis systemic medication , topical agent , parenteral biological/monoclonal antibody agent , within specific time period prior dose . Organ dysfunction clinically significant deviation normal VS , PE , lab , ECG finding ALT , AST total bilirubin exceed 1.5x upper limit normal Screening Major surgery within 3 month Screening Use prescription drug , sedative antihistamine , medical device treatment AD , topical product contain urea and/or ceramides within 14 prior dose Hemoglobin within 5 % low limit normal Abnormal aPTT PT Screening Excessive sun exposure , use tan booth ultraviolet ( UV ) light source 4 week prior dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>eczema</keyword>
</DOC>